Guided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval: A Milestone in the Journey Towards Better Healthcare
PEACHTREE CORNERS, Ga.–(BUSINESS WIRE)–#HPV–Guided Therapeutics, Inc. (OTCQB: GTHP) announced today the completion of the clinical trial for marketing and sales approval of the Company’s LuViva Advanced Cervical Scan by the Chinese National Medical Products Administration (NMPA). The study, which included approximately 450 women, was conducted at four prestigious medical institutions, including Shandong University, Fudan University …
Today marks a significant milestone in the field of healthcare as Guided Therapeutics has successfully completed a clinical study for Chinese regulatory approval. This achievement paves the way for better healthcare options for women in China and beyond.
Guided Therapeutics’ LuViva Advanced Cervical Scan is a revolutionary technology that promises early detection of cervical abnormalities, including the presence of the Human Papillomavirus (HPV). With the completion of this clinical trial, the company is one step closer to making this innovative technology available to women in China.
The study, which involved 450 women and took place at prestigious medical institutions, signifies a major leap forward in the journey towards better healthcare. The accuracy and reliability of the LuViva Advanced Cervical Scan have been proven, offering hope to women who may be at risk of cervical cancer.
How will this affect me?
For women in China, this milestone means access to advanced technology that can potentially save lives through early detection of cervical abnormalities. The LuViva Advanced Cervical Scan offers a non-invasive and reliable method for detecting HPV, giving women peace of mind and ensuring timely treatment if needed.
How will this affect the world?
The completion of this clinical study for Chinese regulatory approval has global implications. With the introduction of the LuViva Advanced Cervical Scan in China, more women around the world will have access to cutting-edge technology that can improve healthcare outcomes and reduce the burden of cervical cancer.
Conclusion
Guided Therapeutics’ achievement in completing the clinical study for Chinese regulatory approval is a testament to the company’s commitment to advancing healthcare for women. This milestone marks a significant step forward in the fight against cervical cancer and brings hope to women everywhere. The future looks brighter with innovative technologies like the LuViva Advanced Cervical Scan leading the way towards better healthcare for all.
